PMPRB finds ultra-rare drug PROCYSBI is excessively priced | Smart & Biggar
On September 1, 2022, a Panel of the Patented Medicine Prices Review Board (PMPRB) issued a decision that the price of Horizon Pharma’s PROCYSBI (cysteamine delayed release capsules)...
Canadian Pharmaceutical Alliance Median International Price Comparison Human Drug Advisory Panel Access Program Patented Medicine Prices Review Board Horizon Pharma
Source: jdsupra.com